SEC Form 4 · accession 0000899243-18-018325
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael W Bonney
Director
Period of report
Jun 25, 2018
Accepted (ET)
Jun 27, 2018 · 4:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001690585
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 25, 2018 | C | 21,847 | — | A | 215,346 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1 | — | Jun 25, 2018 | C | 50,025 | D | — | — | Common Stock | 19,359 | 0 | D |
| Series B Preferred StockF1 | — | Jun 25, 2018 | C | 6,429 | D | — | — | Common Stock | 2,488 | 0 | D |
Explanation of responses
- F1The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.